에 대한 최신 뉴스 Broadstone Net Lease (NYSE:BNL) 주식

Broadstone Net Lease

Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.

Broadstone Net Lease Inc

Rezolve Ai (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>), the company reinventing retail through real-time AI-driven consumer engagement, today announced that it has secured more than $70 million in Annual Recurring Revenue (ARR) months ahead of schedule putting the company on a clear trajectory to surpass its targeted $100 million ARR before the close of 2025.
This achievement marks a pivotal moment in Rezolve Ai's growth journey, having scaled from a standing start earlier this year and now backed by strategic go-to-market and platform integrations with both Microsoft and Google. These alliances have accelerated Rezolve Ai's global reach and commercial scale, reinforcing its position as a leading AI platform purpose-built for commerce.

News

RZLV

Rezolve Ai Surpasses $70M ARR Ahead Of Schedule, On Track To Exceed $100M Target By End Of 2025

AMRX

Amneal Receives FDA Approval For Prednisolone Acetate Ophthalmic Suspension

Researchers at the John Innes Centre (JIC) have discovered a genetic mutation with the potential to enhance nutrient uptake and reduce the need for artificial fertilizers
Cibus and JIC have agreed on a collaboration with the potential to introduce the trait into several commercial crops
Cibus previously announced the successful editing of Canola plants with this mutation and looks forward to further testing and trait validation
SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. ("Cibus" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today confirmed its continuing collaboration with the John Innes Centre (JIC). Cibus applauds the JIC breakthrough discovery, published earlier this year in the journal Nature, of a biological mechanism that makes plant roots more welcoming to beneficial soil microbes. Cibus and JIC have been collaborating to translate JIC's discovery into a nutrient use efficiency (NUE) trait for a number of crops, including canola/oilseed rape. If successfully developed, the NUE trait would lead to improved nutrient uptake thereby reducing the use of nitrate and phosphate fertilizers without compromising yields.

CBUS

Cibus Confirms Continuing Collaboration With John Innes Centre To Revolutionize Fertilizer Use In Farming

La Rosa Holdings Corp. (NASDAQ:&nbsp;LRHC) ("La Rosa" or the "Company"), a real estate and PropTech company, &nbsp;today announced that it has entered into a non-binding Letter of Intent ("LOI") with MiiX Financial Holdings Trust ("MiiX') to jointly implement and distribute MiiX's proprietary residential financing solutions for all credit levels across La Rosa's network of approximately 2,900 agents and all of its listings.
The partnership is intended to establish a long-term strategic alliance between the two companies, centered on MiiX's groundbreaking platform that eliminates traditional credit requirements and provides accessible homeownership solutions for buyers of all income and credit levels. The platform also introduces advanced real estate monetization tools capable of enabling same-day property purchasing, trading, settlement, and recordings similar to the speed and efficiency of financial markets.
Under the LOI, La Rosa and MiiX will work toward a definitive agreement that is expected to include the following key terms:
<ul>
<li>La Rosa and/or a newly formed division or subsidiary, will become the exclusive real estate partner for MiiX's proprietary financing technology platform.</li>
<li>MiiX will integrate its products directly into La Rosa's agent workflows and property listings, potentially creating added value for both agents and homebuyers.</li>
<li>All La Rosa listings will feature access to financing solutions, aimed at increasing access to homeownership and accelerating the efficiency of real estate transactions.</li>
</ul>
The parties will collaboratively determine the operational structure and deployment timeline as they advance toward a definitive agreement.

LRHC

La Rosa Holdings Signs LOI With MiiX Financial To Deploy Inclusive Home Financing Platform Across Network

Upon completion of the acquisition, M2i Global will receive common shares of Volato Group stock such that M2i Global will own approximately 90% of the total issued and outstanding shares of common stock of Volato Group on an as-converted and fully diluted basis (excluding any outstanding public warrants for SOAR common stock) and the current shareholders of Volato Group will own approximately 10% of the total issued and outstanding shares of SOAR common stock on an as-converted and fully diluted basis (excluding any outstanding public warrants for SOAR common stock). Based on current market prices, this structure represents an increase in value for SOAR shareholders while aligning MTWO with an NYSE American listing and public equity currency.
 &nbsp;

SOAR

Volato Group To Acquire M2i Global; M2i Global To Receive Volato Common Shares Such That M2i Will Own ~90% Of Total Issued And Outstanding Shares

~ Andrew J. Trontis, MD from Progressive Spine and Orthopaedics, (Englewood, NJ) Completes Initial Case Series ~
LOS GATOS, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 12, 2025 / Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the completion of an initial case series utilizing the Catamaran&#xAE; SI Joint Fusion System (the "Catamaran") to immobilize &amp; stabilize the SI Joint providing added support at the base of a lumbar or thoracolumbar fusion. The case series was completed by Andrew J. Trontis, MD from Progressive Spine &amp; Orthopaedics in Englewood, New Jersey. As <a href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/tenon-medicalr-announces-fda-clearance-of-catamaranr-si-joint-fusion--1004697">announced previously</a> by the Company, the Catamaran recently received an expanded indication for use from the U.S. Food and Drug Administration (FDA). The Catamaran is now approved to augment immobilization and stabilization of the SI joint for patients undergoing sacropelvic fixation as part of a lumbar fusion.

Biotech

General

TNON

Tenon Medical Announces Completion Of Initial Case Series Using Catamaran SI Joint Fusion System

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>). &#8220;I think it's a <a href="https://www.benzinga.com/quote/UNP/analyst-ratings">really good stock to own,&#8221; he added.</a>
Supporting his view, BofA Securities analyst Ken Hoexter, on May 16, maintained Union Pacific with a Buy rating and raised the price target from $256 to $262.
&#8220;I'm getting tired of the orphan drug model,&#8221; Cramer said when asked about BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>). &#8220;I don't think it works now.&#8221;
As per the recent news, BioMarin, on May 16, agreed to acquire Inozyme for $4.00 per share in all-cash transaction for total consideration of about $270 million.
Cramer said he likes the model of ARS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>). &#8220;It's a great flier. Someone needs that technology, someone's going to pay for it,&#8221; he added.
Lending support to his choice, ARS Pharmaceuticals, on May 14, posted better-than-expected sales for the first quarter.
&#8220;I was prepared for disappointment and I got it,&#8221; Cramer said when asked about GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>). &#8220;I just do not want enterprise software. I think they're all too expensive.&#8221;
Supporting his view, GitLab, on June 10, issued second-quarter sales guidance with its midpoint below estimates. GitLab sees second-quarter adjusted EPS of between 16 and 17 cents, versus the 16 cent estimate, and revenue of between $226 million and $227 million, versus the $227.16 million analyst estimate.
The Mad Money host said he would buy NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) if it does an offering here. &#8220;I'd wait for the stock offering after what happened with Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) tonight,&#8221; he added.
UBS analyst Jon Windham, on May 29, maintained NuScale Power with a Neutral and raised the price target from $17 to $34.
Price Action:
<ul class="wp-block-list">
<li>BioMarin Pharmaceutical shares fell 0.6% to settle at $57.16 on Wednesday.</li>
<li>NuScale Power shares jumped 20.4% to close at $41.60.</li>
<li>Union Pacific fell 0.4% to settle at $225.72 on Wednesday.</li>
<li>GitLab shares fell 10.6% to close at $43.37.</li>
<li>ARS Pharmaceuticals shares fell 2.4% to settle at $14.34.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Markets

Media

Trading Ideas

BMRN

GTLB

OKLO

SPRY

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs

Telsey Advisory Group analyst Dana Telsey maintains J.Jill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) with a Market Perform and lowers the price target from $21 to $17.

Price Target

Analyst Ratings

JILL

Telsey Advisory Group Maintains Market Perform on J.Jill, Lowers Price Target to $17

<a href="https://www.globenewswire.com/Tracker?data=CxrsxD5uGK6ynUyVQZ_galOWTmNxxCUp-60-pQD6jcA9AEhoBEUQqJBFSy8g4OvMjFfDGntItw4JT0T6SPs6f6_UO2EnigIcdNFqShdUezE=">AIM ImmunoTech Inc.</a> (OTC:<a href="https://www.benzinga.com/stock/AIMID#OTC">AIMID</a>) (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) ("AIM" or the "Company") today announced that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the Company's common stock on the NYSE American. The NYSE Regulation staff determined that the Company's common stock was now trading above the threshold of low selling price issues as further defined by Section 1003(f)(v) of the NYSE American Company Guide. AIM's common stock is expected to resume trading on the NYSE American on Tuesday, June 17, 2025, under the symbol "AIM" and CUSIP 00901B303.

AIMI

NYSE Regulation Withdraws Delisting Determination, AIM ImmunoTech Trading To Resume On June 17, 2025

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer discretionary sector.
<h3 class="wp-block-heading">Movado Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOV#NYSE">MOV</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 8.76%</li>
<li>BWS Financial analyst Hamed Khorsand maintained a Buy rating with a price target of $31.5 on June 2, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Benchmark analyst Michael Legg reiterated a Buy rating with a price target of $41 on June 3, 2024. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On May 29, Movado Group reported worse-than-expected first-quarter financial results and announced it will withhold its FY26 guidance amid tariffs and planned price hikes.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest MOV <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612"><img loading="lazy" decoding="async" width="922" height="825" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075942/image-188.png" alt="" class="wp-image-947523" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075942/image-188.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075942/image-188-300x268.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12075942/image-188-768x687.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 8.01%</li>
<li>JP Morgan analyst Michael Rehaut maintained a Neutral rating and slashed the price target from $109 to $89 on April 28, 2025. This analyst has an accuracy rate of 71%.</li>
<li>RBC Capital analyst Mike Dahl maintained an Underperform rating and cut price target from $76 to $74 on Oct. 25, 2024. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On April 23, Whirlpool issued FY25 adjusted EPS guidance above estimates.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest WHR <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612"><img loading="lazy" decoding="async" width="895" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080015/image-189.png" alt="" class="wp-image-947526" style="width:558px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080015/image-189.png 895w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080015/image-189-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080015/image-189-768x710.png 768w" sizes="(max-width: 895px) 100vw, 895px" /></a></figure>
<h3 class="wp-block-heading">Designer Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 7.78%</li>
<li>UBS analyst Jay Sole maintained a Neutral rating and cut the price target from $3.5 to $3 on June 11, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating and lowered the price target from $5 to $4 on June 11, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: On June 10, Designer Brands reported worse-than-expected first-quarter financial results and withdrew its FY25 guidance due to macroeconomic uncertainty.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest DBI <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612"><img loading="lazy" decoding="async" width="917" height="812" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080054/image-190.png" alt="" class="wp-image-947527" style="width:647px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080054/image-190.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080054/image-190-300x266.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080054/image-190-768x680.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Wall Street's Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields

ImmunoPrecise Antibodies Announces In Vitro Results Demonstrating Its GLP-1RA Peptide Sequences Achieve Comparable Or Superior Receptor Activation To Semaglutide

As one of the supermajors – a term used to describe the world's largest publicly traded companies – Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) historically commands significant relevance. Much of the company's influence centers on its integrated business, which means that it controls various stages of the hydrocarbon sector, from exploration and production (upstream) to refining and marketing (downstream). However, shifting macro tides have added significant wrinkles to the narrative of XOM stock.
On the optimistic front, recent<a href="https://www.benzinga.com/markets/commodities/25/06/45897276/oil-etfs-surge-over-6-as-trump-orders-middle-east-evacuation-amid-iran-tensions-warns-region-could-be-dangerous"> geopolitical dynamics</a> have led to a cynical lift in hydrocarbon demand. During the midweek session, crude oil prices – along with the exchange-traded funds tracking the commodity – surged to a two-month high off escalating tensions in the Middle East. President Donald Trump announced that U.S. personnel stationed in the region were being moved out because "it could be a dangerous place."
At the heart of the escalation are mounting concerns that Israel may soon launch an<a href="https://www.nytimes.com/2025/06/11/us/politics/iran-us-iraq-diplomats-middle-east.html"> attack</a> on Iran. If so, a retaliatory response by the Iranian government can potentially jeopardize U.S. personnel, necessitating their departure. On Wednesday, Brent crude futures rallied nearly 5%, while XOM stock gained just under 2%. For the year, the security is up 1.62%, finally breaking into positive territory.
On a less controversial and cynical note, Exxon Mobil is doubling down on its efforts to promote<a href="https://www.benzinga.com/news/contracts/25/05/45284262/exxon-mobil-says-deal-with-japans-marubeni-to-boost-jobs-global-energy-supply"> industrial decarbonization</a>, which involves carbon capture, storage and blue hydrogen. In fairness, these are long-term initiatives, which may take some time to play out for XOM stock. Nevertheless, the company is making significant progress through high-level contracts and partnerships.
Of course, not everything is rosy for the bulls. In particular, there is growing evidence that oil demand may have reached a peak. About a month-and-a-half ago, reports emerged that Saudi Arabia told its allies and industry participants that the oil-rich nation is prepared to endure a<a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45135059/oil-sinks-below-57-on-opec-supply-speculation-bear-market-deepens"> longer stretch of low prices</a> without further supply cuts. Subsequently, without geopolitical shocks, the oil market may lack upside catalysts.
Another vexing issue for hydrocarbon providers is the<a href="https://www.benzinga.com/25/04/44755934/us-q1-ev-sales-data-shows-106-yoy-growth-tesla-experiences-decline-but-still-dominates-domestic-ev-sales"> rise of the electric vehicle</a>. Earlier this year, Cox Automotive revealed that EV sales in the U.S. have grown by over 10% on a year-over-year basis, hitting 294,250 units sold in the first quarter of 2025. With the trend showing no signs of slowing down, the EV bull market could potentially crimp XOM stock.
The Direxion ETFs: With key narratives supporting both sides of the sentiment spectrum, swing traders may find utility with Direxion's sector-specific ETFs. For those who are bullish on Exxon Mobil, they may consider the Direxion Daily XOM Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMX#NASDAQ">XOMX</a>), which seeks the daily investment results of 200% of the performance of XOM stock. On the other hand, pessimists may target the Direxion Daily XOM Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMZ#NASDAQ">XOMZ</a>), which seeks 100% of the inverse performance of the namesake equity.
Primarily, both ETFs offer a convenient mechanism for speculative activities. Ordinarily, if a trader wanted to use leverage on XOM stock – or to open a short position – the options market is the most obvious place to look. However, options strategies can be complicated. With Direxion ETFs, the underlying units can be bought and sold much like any other publicly traded security. Therefore, the learning curve is relatively shallow.
Still, prospective participants should realize that there are significant risks involved with Direxion ETFs. Inverse funds and especially leveraged funds tend to be far more volatile than funds that track the benchmark equity indices. Also, these specialized funds are designed for exposure lasting no longer than one day. Holding beyond the recommended period may lead to value decay due to the daily compounding effect.
The XOMX ETF: Introduced in late April, the XOMX ETF entered the market at an awkward time. Still, the aforementioned geopolitical events have lifted sentiment dramatically.
<ul class="wp-block-list">
<li>On Wednesday, the XOMX ETF gained over 3% while during the trailing five sessions, it moved up 14.5%, sending the price action firmly above the 20-day exponential moving average (EMA).</li>
<li>Given the youth of the fund, it's difficult to make projections. However, traders should watch volume levels, which haven't confirmed the upswing in price.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1002" height="633" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080215/image-191.png" alt="" class="wp-image-947531" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080215/image-191.png 1002w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080215/image-191-300x190.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080215/image-191-768x485.png 768w" sizes="(max-width: 1002px) 100vw, 1002px" /></figure>
The XOMZ ETF: Also making its debut in late April, the inverse XOMZ fund got off to a strong start. However, the geopolitical temperature sank sentiment.
<ul class="wp-block-list">
<li>During the midweek session, the XOMZ ETF slipped just over 2%, while the trailing five sessions saw a loss of 1.83%. Currently, the price action is well below the 20-day EMA.</li>
<li>Due to renewed bullishness in hydrocarbons, volume levels have tanked for the inverse fund. However, momentum could rebound once the geopolitical framework normalizes.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1002" height="633" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080215/image-191.png" alt="" class="wp-image-947530" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080215/image-191.png 1002w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080215/image-191-300x190.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12080215/image-191-768x485.png 768w" sizes="(max-width: 1002px) 100vw, 1002px" /></figure>
Featured image by <a href="https://pixabay.com/users/ptra-359668/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=1044575">Petra</a> on <a href="https://pixabay.com/photos/oil-financial-support-sasketchewan-1044575/">Pixabay</a>.

Short Ideas

Technicals

ETFs

XOMX

XOMZ

Rising Hydrocarbon Sentiment Amid Tense Environment Bolsters Relevance For Direxion's XOMX, XOMZ ETFs

Across the recent three months, 6 analysts have shared their insights on Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $47.67, with a high estimate of $56.00 and a low estimate of $34.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.69%. 
<img src="https://www.benzinga.com/files/images/story/2025/1749729700_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Calix is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$53.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$53.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$34.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Calix. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Calix compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Calix's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Calix's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CALX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Calix analyst ratings.</a>
<h2>Discovering Calix: A Closer Look</h2>
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East &amp; Africa, Europe, Asia Pacific and other markets.
<h3>Calix: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Calix's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -2.68% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Calix's net margin excels beyond industry benchmarks, reaching -2.17%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Calix's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.62%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Calix's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.52%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Calix's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CALX

Demystifying Calix: Insights From 6 Analyst Reviews

Many big tech companies, including startups, are foraying into the emerging field of quantum computing. Out of the 300 quantum computing patents issued in 2025, two companies have received the most.
What Happened: International Business Machines Corp. and Alphabet Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google appear to have made significant investments in the quantum computing space on a year-to-date basis.
According to the data shared by Martin Shkreli, there was a steep drop-off in issued patents after IBM and Google, suggesting that other companies are either smaller players or not prioritizing quantum computing as heavily.
IonQ Inc., D-Wave Quantum Inc., PsiQuantum, Quantinuum, and Intel Corp., followed the first two firms.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I looked at every quantum computing patent issued this year (&gt;300) so you don&#39;t have to. A few takeaways 1) QC is a very small space with only two companies seriously investing (rest are startups or not serious) 2) Craig Gidney is 1337 (1/2) <a href="https://t.co/rqtcbvpUO9">pic.twitter.com/rqtcbvpUO9</a>
&mdash; Martin Shkreli (@MartinShkreli) <a href="https://twitter.com/MartinShkreli/status/1932861083938635989?ref_src=twsrc%5Etfw">June 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Furthermore, he highlighted that Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), and JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) also hold quantum patents, which he describes as &#8220;big company spend.&#8221;
Large corporations often invest in emerging technologies like quantum computing to hedge against future disruptions, even if they're not leading the field.
Shkreli also notes that companies like Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) are working on Quantum Key Distribution (QKD) and quantum networking patents. QKD uses quantum mechanics to secure communications, offering theoretically unbreakable encryption.
Lastly, Shkreli suggests that Microsoft Corp.&#8217;s patent output doesn't match its spending or public statements, implying they may be focusing more on development or partnerships rather than patenting their work.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">3) China is surprisingly involved at the level of top companies (Alibaba, Tencent) 4) Wells Fargo, Bank of America, JPMorgan all have some quantum patents (emblematic of &quot;big company spend&quot; that I&#39;ve been talking about) 5) Cisco and other networking players have some QKD/quantum…
&mdash; Martin Shkreli (@MartinShkreli) <a href="https://twitter.com/MartinShkreli/status/1932861086224494849?ref_src=twsrc%5Etfw">June 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45888626/nvidia-apple-amazon-microsoft-and-alphabets-insitutional-investors-sold-8-4-billion-shares-in-q1-filings-reveal">Nvidia, Apple, Amazon, Microsoft, And Alphabet&#8217;s Institutional Investors Sold 8.4 Billion Shares In Q1, Filings Reveal</a>
Why It Matters: The evolving quantum computing space relies on qubits, which, unlike classical bits in traditional computers, can superpose and entangle 0 and 1 to solve complex problems.
While still in the development stage, many publicly listed firms are involved in their research and development. Here&#8217;s a list of a few companies and an exchange-traded fund that tracks such companies.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>)</td>
<td>28.00%</td>
<td>66.58%</td>
</tr>
<tr>
<td>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)</td>
<td>-6.21%</td>
<td>-0.43%</td>
</tr>
<tr>
<td>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</td>
<td>2.27%</td>
<td>-32.77%</td>
</tr>
<tr>
<td>Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>)</td>
<td>8.61%</td>
<td>40.71%</td>
</tr>
<tr>
<td>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>12.91%</td>
<td>7.16%</td>
</tr>
<tr>
<td>IonQ Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>)</td>
<td>-7.89%</td>
<td>399.37%</td>
</tr>
<tr>
<td>D-Wave Quantum Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>)</td>
<td>72.01%</td>
<td>1325.00%</td>
</tr>
<tr>
<td>Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>)</td>
<td>-37.40%</td>
<td>1127.45%</td>
</tr>
<tr>
<td>Quantum Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>)</td>
<td>1.12%</td>
<td>2864.06%</td>
</tr>
<tr>
<td>Defiance Quantum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTUM#NASDAQ">QTUM</a>)</td>
<td>8.24%</td>
<td>38.92%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell on Wednesday. The SPY was down 0.29% at $601.36, while the QQQ declined 0.34% to $532.41, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
The futures of the S&amp;P 500, Dow Jones, and Nasdaq 100 indices fell on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45886571/gary-blacks-2021-tsla-stock-exit-dodged-a-30-drop-can-valuation-discipline-outsmart-teslas-2025-robotaxi-hype">Gary Black&#8217;s 2021 TSLA Stock Exit Dodged A 30% Drop: Can Valuation Discipline Outsmart Tesla&#8217;s 2025 Robotaxi Hype</a></li>
</ul>
Photo courtesy: JHVEPhoto / Shutterstock.com

Equities

CSCO

GOOG

GOOGL

INTC

IONQ

MSFT

QBTS

QTUM

QUBT

RGTI

IBM, Google Emerge As Top Investors In Quantum Computing With Most Patents Issued In 2025: 'Only Two Companies Seriously Investing,' Says Martin Shkreli

Telsey Advisory Group analyst Dana Telsey maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Market Perform and maintains $24 price target.

VSCO

Telsey Advisory Group Maintains Market Perform on Victoria's Secret, Maintains $24 Price Target

6 analysts have shared their evaluations of Anglogold Ashanti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Anglogold Ashanti, revealing an average target of $44.42, a high estimate of $53.00, and a low estimate of $35.00. This upward trend is apparent, with the current average reflecting a 20.05% increase from the previous average price target of $37.00.
<img src="https://www.benzinga.com/files/images/story/2025/1749729689_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Anglogold Ashanti among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Reagor</td>
<td>Roth Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$52.00</td>
<td>-</td>
</tr>
<tr>
<td>Tanya Jakusconek</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$43.50</td>
<td>$42.00</td>
</tr>
<tr>
<td>Patrick Jones</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Leroy Mnguni</td>
<td>HSBC</td>
<td>Announces</td>
<td>Reduce</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Tanya Jakusconek</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$42.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Josh Wolfson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$41.00</td>
<td>$39.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Anglogold Ashanti. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Anglogold Ashanti compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Anglogold Ashanti's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Anglogold Ashanti's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Anglogold Ashanti analyst ratings.</a>
<h2>Unveiling the Story Behind Anglogold Ashanti</h2>
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
<h3>Anglogold Ashanti's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Anglogold Ashanti displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 67.63%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Anglogold Ashanti's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 22.57%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Anglogold Ashanti's ROE stands out, surpassing industry averages. With an impressive ROE of 6.61%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Anglogold Ashanti's ROA stands out, surpassing industry averages. With an impressive ROA of 3.34%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Anglogold Ashanti's debt-to-equity ratio stands notably higher than the industry average, reaching 0.33. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Anglogold Ashanti Stock

DoubleVerify Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.23, along with a high estimate of $24.00 and a low estimate of $14.00. A decline of 10.77% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1749729678_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of DoubleVerify Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Andrew Marok</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Andrew Marok</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Matthew Cost</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>Michael Graham</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.50</td>
<td>$20.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Vikram Kesavabhotla</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DoubleVerify Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DoubleVerify Holdings compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of DoubleVerify Holdings's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into DoubleVerify Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on DoubleVerify Holdings analyst ratings.</a>
<h2>Get to Know DoubleVerify Holdings Better</h2>
DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. Its solutions provide advertisers with unbiased data analytics that enable them to increase the effectiveness, quality, and return on their digital advertising investments. Its DV Authentic Ad, a proprietary metric of digital media quality, measures whether a digital ad was delivered in a brand-suitable environment, fully viewable, by a real person, and in the intended geography. The company's software interface, DV Pinnacle, delivers these metrics to customers in real time, allowing them to access critical performance data on their digital transactions. Geographically, the company operates in the United States and also has a presence in Germany, Singapore, France, Canada, Japan, and other countries.
<h3>DoubleVerify Holdings's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: DoubleVerify Holdings's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 17.25%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: DoubleVerify Holdings's net margin is impressive, surpassing industry averages. With a net margin of 1.43%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.22%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): DoubleVerify Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.19%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About DoubleVerify Holdings Stock

Analysts' ratings for Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of $255.00, and a low estimate of $115.00. This current average has decreased by 10.94% from the previous average price target of $214.27. 
<img src="https://www.benzinga.com/files/images/story/2025/1749729668_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Biogen by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$169.00</td>
<td>$207.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$220.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$187.00</td>
<td>$241.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$255.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$199.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$197.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$152.00</td>
<td>$157.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Biogen. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Biogen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Biogen's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Biogen analyst ratings.</a>
<h2>About Biogen</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>Key Indicators: Biogen's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Biogen's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 6.13%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Biogen's net margin is impressive, surpassing industry averages. With a net margin of 9.89%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Biogen's ROE stands out, surpassing industry averages. With an impressive ROE of 1.43%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Biogen's ROA stands out, surpassing industry averages. With an impressive ROA of 0.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Biogen's debt-to-equity ratio is below the industry average at 0.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIIB

Demystifying Biogen: Insights From 11 Analyst Reviews

8 analysts have shared their evaluations of Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Dave, presenting an average target of $200.12, a high estimate of $250.00, and a low estimate of $125.00. Witnessing a positive shift, the current average has risen by 32.03% from the previous average price target of $151.57.
<img src="https://www.benzinga.com/files/images/story/2025/1749729657_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Dave's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$250.00</td>
<td>-</td>
</tr>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$239.00</td>
<td>$206.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$229.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$200.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Jacob Stephan</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$177.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$202.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$179.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dave. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dave compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Dave's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Dave's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DAVE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dave analyst ratings.</a>
<h2>All You Need to Know About Dave</h2>
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
<h3>Dave: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Dave's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 46.65% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Dave's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 26.68%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Dave's ROE excels beyond industry benchmarks, reaching 15.06%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Dave's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.37% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.38, Dave adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DAVE

Analyst Expectations For Dave's Future

In the last three months, 9 analysts have published ratings on Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Fabrinet, revealing an average target of $243.89, a high estimate of $290.00, and a low estimate of $176.00. Experiencing a 1.48% decline, the current average is now lower than the previous average price target of $247.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1749729646_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Fabrinet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$234.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$235.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$280.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Dave Kang</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$176.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$280.00</td>
<td>$280.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fabrinet. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Fabrinet compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Fabrinet's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Fabrinet's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Fabrinet analyst ratings.</a>
<h2>About Fabrinet</h2>
Fabrinet provides advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advanced optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advanced packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.
<h3>Financial Milestones: Fabrinet's Journey</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining Fabrinet's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 19.17% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Fabrinet's net margin excels beyond industry benchmarks, reaching 9.32%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Fabrinet's ROE excels beyond industry benchmarks, reaching 4.34%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Fabrinet's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.15% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.0, Fabrinet adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Fabrinet's Future

Press Releases

Broadstone Net Lease Adds $117.4 Million to its Committed Pipeline of Build-to-Suit Development Commitments and Schedules Fourth Quarter 2024 Earnings Release and Conference Call

Broadstone Net Lease Announces Tax Treatment of 2024 Dividends

Broadstone Net Lease Provides Updates on Its Board of Directors

Broadstone Net Lease Announces Fourth Quarter and Full Year 2024 Results

Broadstone Net Lease Announces $1.5 Billion of Extended and Increased Credit Facilities

Broadstone Net Lease Schedules First Quarter 2025 Earnings Release and Conference Call

Broadstone Net Lease Partners with Prologis, Inc. on a $78.2 Million Build-to-Suit Development

Broadstone Net Lease Announces First Quarter 2025 Results

Keller Williams Announces Executive Appointments

Broadstone Net Lease Provides an Update on Recent Business Activity and Participation at Nareit's REITweek 2025 Annual Conference

Comments

Broadstone Net Lease

뉴스

에 대한 최신 뉴스 Broadstone Net Lease (NYSE:BNL) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌